Is ibrutinib/ibrutinib already included in the scope of medical insurance reimbursement?

Ibrutinib/Ibrutinib (Ibrutinib) is a targeted drug mainly used to treat B cell-related malignant tumors. The drug prevents the proliferation and spread of cancer cells by inhibiting Bruton's tyrosine kinase (BTK). It has been approved globally and is also available in the Chinese market. Especially in the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), **Waldenstrom's macroglobulinemia (WM)** and other diseases, remarkable therapeutic effects have been achieved.

According to the relevant policies of the National Medical Insurance Administration, ibrutinib has been included in China’s medical insurance, providing a more affordable treatment option for the majority of patients. Taking ibrutinib with a specification of 140mg*90 tablets as an example, its market price is approximately more than RMB 10,000. For some patients, especially those requiring long-term treatment, medical insurance reimbursement undoubtedly eases the financial burden.

Indications for ibrutinib in medical insurance include:

1. Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

2. Mantle cell lymphoma (MCL), especially in patients who have received at least one type of therapy

3. Waldenstrom’s macroglobulinemia (WM)

Within the scope of medical insurance reimbursement, patients can receive treatment according to the drug instructions according to their own condition. According to the policies of different regions and hospitals, the specific reimbursement ratio for patients may vary, and doctors usually need to issue relevant treatment plans and drug prescriptions.

In short, as an effective anti-cancer drug, ibrutinib's medical insurance reimbursement in China provides patients with certain financial support, allowing more patients to benefit from this treatment option, especially among patients who have poor response to traditional treatments.

Reference materials:https://www.imbruvica.com/